ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

68Ga-pentixafor PET/CT in the localization diagnosis of primary aldosteronism concurrent subclinical cushing’s syndrsome: two case reports

  • 期刊论文

  • 发表日期：

    2024年6月24日

查看全文
  • Xin Wei,
  • Feifei Wu,
  • Haoyu Dong,
  • Ying Jing,
  • Ying Song,
  • Hua Pang,
  • Jing Chen,
  • Zhipeng Du,
  • Wenwen He,
  • Linqiang Ma,
  • Yue Wang,
  • Jinbo Hu,
  • Qifu Li,
  • Shumin Yang,
  • Mei Mei,
  • Suxin Luo,
  • Kangla Liao,
  • Yao Zhang,
  • Yunfeng He,
  • Yihong He,
  • Ming Xiao,
  • Bin Peng

摘要

Purpose

Adrenal venous sampling (AVS) is recommended for subtyping primary aldosteronism (PA). However, in cases of PA, concurrent subclinical Cushing’s syndrome (SCS) has the potential to confound AVS results. Pentixafor, a CXC chemokine receptor type 4–specific ligand, has been reported as a promising marker to evaluate functional nature of adrenal adenomas. This study aims to investigate the clinical value of Gallium-68 Pentixafor Positron Emission Tomography–Computed Tomography (68Ga-Pentixafor PET/CT) in the localization diagnosis of patients with PA plus SCS.

Methods

Two patients with a confirmed diagnosis of PA plus SCS underwent AVS and 68Ga-Pentixafor PET/CT.

Results

AVS results revealed no lateralization for both patients while 68Ga-Pentixafor PET/CT showed a unilateral adrenal nodule with increased uptake of 68Ga-Pentixafor. Unilateral adrenalectomy was performed based on the results of 68Ga-Pentixafor PET/CT. Subsequently, complete biochemical remission of autonomous aldosterone and cortisol secretion were achieved in both cases.

Conclusions

68Ga-Pentixafor PET/CT shows promising potential for the localization of aldosterone and cortisol co-secreting adrenal adenoma in patients with PA plus SCS.